Koirala Mahesh, DiPaola Mario
Therabene Inc., Mansfield, MA 02048, USA.
Curr Issues Mol Biol. 2024 Feb 22;46(3):1713-1730. doi: 10.3390/cimb46030111.
The persistent threat of cancer remains a significant hurdle for global health, prompting the exploration of innovative approaches in the quest for successful therapeutic interventions. Cyclin-dependent kinase 9 (CDK9), a central player in transcription regulation and cell cycle progression, has emerged as a promising target to combat cancer. Its pivotal role in oncogenic pathways and the pressing need for novel cancer treatments has propelled CDK9 into the spotlight of drug discovery efforts. This article presents a comprehensive study that connects a multidisciplinary approach, combining computational methodologies, experimental validation, and the transformative Proteolysis-Targeting Chimera (PROTAC) technology. By uniting these diverse techniques, we aim to identify, characterize, and optimize a new class of degraders targeting CDK9. We explore these compounds for targeted protein degradation, offering a novel and potentially effective approach to cancer therapy. This cohesive strategy utilizes the combination of computational predictions and experimental insights, with the goal of advancing the development of effective anticancer therapeutics, targeting CDK9.
癌症的持续威胁仍然是全球健康的重大障碍，促使人们在寻求成功的治疗干预措施时探索创新方法。细胞周期蛋白依赖性激酶9（CDK9）是转录调控和细胞周期进程的核心参与者，已成为对抗癌症的一个有前景的靶点。它在致癌途径中的关键作用以及对新型癌症治疗方法的迫切需求，使CDK9成为药物研发努力的焦点。本文呈现了一项综合研究，该研究将多学科方法相结合，包括计算方法、实验验证以及变革性的蛋白酶靶向嵌合体（PROTAC）技术。通过整合这些不同的技术，我们旨在识别、表征和优化一类新的靶向CDK9的降解剂。我们探索这些化合物用于靶向蛋白质降解，为癌症治疗提供一种新颖且可能有效的方法。这种连贯的策略利用了计算预测和实验见解的结合，目标是推进针对CDK9的有效抗癌治疗药物的开发。
